Serious side effects, including leg, foot, and other amputation, have been associated with a new class of diabetes drugs known as SGLT-2 inhibitors. Accordingly, the FDA has required black boxed warnings for amputation risks for glucose-controlling medications such as Invokana.
Topics: Health News, Amputation, FDA, Diabetes Drug, The Law Offices of Foster & Houston, Amputation Lawsuit, FANDHLAW, Ryan Foster, Foster & Houston, Diabetes Drug Lawsuit, Amputation Compensation, Amputation Law, Amputation Attorney, Amputation Lawyer, Leg Amputation, Leg Amputation Attorney, Leg Amputation Law, Leg Amputation Lawsuit, Foot Amputation, Foot Amputation Compensation, Foot Amputation Attorney, Foot Amputation Lawyer, Invokana Compensation, Invokana Attorney, Invokana Law, Invokana Lawyer, Invokana Lawsuit, Type 2 Diabetes Medication, Diabetes Medication, SGLT-2 Inhibitors, SGLT-2 Inhibitors Lawsuit, Leg Amputation Compensation, Leg Amputation Lawyer, Foot Amputation Law, Foot Amputation Lawsuit, Invokana, Type 2 Diabetes
Takeda Pharmaceutical Co., the manufacturer of Actos, proposed $2.2 billion to settle thousands of lawsuits, according to Bloomberg. As of April 2015 more than 8,000 lawsuits had been filed against the diabetes medicine claiming hidden cancer risks.